Requiring a new warning about this risk to be added to the prescribing information of all SGLT2 inhibitors and to the patient Medication Guide.
SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication – Regarding Rare Occurrences of a Serious Infection of the Genital Area
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA In Brief: FDA Hosts Third Summit Focused on Reducing the Availability of Opioids Online
- Coronavirus (COVID-19) Update: September 17, 2021
- Federal Court Enters Consent Decree Against Florida Compounder, Prohibiting Manufacture and Distribution of Drugs Due to Insanitary Conditions
- Potential for False Positive Results with Abbott Molecular Inc. Alinity m SARS-CoV-2 AMP and Alinity m Resp-4-Plex AMP Kits – Letter to Clinical Laboratory Staff and Health Care Providers